By Deena Beasley June 25 (Reuters) – Launch prices for prescription medicines approved by U.S. regulators in 2025 fell from the previous year, but remained high at a median of $216,000 due to
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
ARCHIVE: A look at female drivers in F1 as the sport marks 50 years since last female racer
VIDEO SHOWS: ARCHIVE FOOTAGE AND STILL PHOTOGRAPHS OF FEMALE DRIVERS WHO HAVE RACED / TESTED…
BRIEF-Yunnan Jinxun Resources Sees H1 2026 Unaudited Net Profit Of RMB210 Million–RMB240 Million
Aug 10 (Reuters) - Yunnan Jinxun Resources Co Ltd: * EXPECTS H1 2026 UNAUDITED NET…
Unitree's Shanghai IPO more than 8,000 times oversubscribed by retail investors
BEIJING/SHANGHAI, Aug 10 (Reuters) - Chinese robot maker Unitree said on Monday its $900 million…
